Tevogen Bio (NASDAQ:TVGN) Lowered to “Strong Sell” Rating by Wall Street Zen

Tevogen Bio (NASDAQ:TVGN) was downgraded by equities researchers at Wall Street Zen to a “strong sell” rating in a research report issued on Saturday.

Other analysts have also recently issued research reports about the stock. D. Boral Capital cut shares of Tevogen Bio from a “buy” rating to a “hold” rating in a research note on Wednesday, March 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Tevogen Bio in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Tevogen Bio presently has an average rating of “Reduce” and an average price target of $100.00.

Tevogen Bio Stock Performance

Shares of NASDAQ TVGN opened at $5.22 on Friday. Tevogen Bio has a one year low of $4.89 and a one year high of $75.50. The firm has a market capitalization of $20.72 million, a P/E ratio of -0.55 and a beta of -0.76. The company’s fifty day moving average is $12.65 and its two-hundred day moving average is $23.25.

Institutional Investors Weigh In On Tevogen Bio

Several hedge funds have recently made changes to their positions in the business. Deutsche Bank AG grew its position in shares of Tevogen Bio by 304.1% in the fourth quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after purchasing an additional 130,738 shares during the period. Bridgeway Capital Management LLC lifted its position in Tevogen Bio by 66.7% during the third quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock worth $65,000 after buying an additional 33,000 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in Tevogen Bio by 126.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after buying an additional 152,572 shares during the last quarter.

About Tevogen Bio

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.